While all of these GLP-1-based medicines demonstrate some success in lowering body weight and HbA 1c levels, GLP-1 and its analogues are not without unwanted side effects
Semaglutide works for the majority who try it, but it doesnt work the same way for everyone
The growing popularity of GLP-1 receptor agonists, especially semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), both of which are FDA-approved for type 2 diabetes and/or obesity and, has been accompanied by considerable social media attention and discussion, from which thorough analyses of user-generated data have emerged highlighting reductions in alcohol-seeking motivation, decreased drinking behavior, and altered subjective responses to alcohol (Arillotta et al
5a and Extended Data Fig
International researchers face a patchwork of regulations that vary significantly by country
If there are fewer links for a specific tool, updates are provided on the platform with the highest count in backlink volume because of delays in indexation
